Qternmet Xr patents expiration

QTERNMET XR's oppositions filed in EPO
QTERNMET XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(a month ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(1 year, 9 months from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(4 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(7 years from now)

Qternmet Xr is owned by Astrazeneca Ab.

Qternmet Xr contains Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride.

Qternmet Xr has a total of 7 drug patents out of which 1 drug patent has expired.

Expired drug patents of Qternmet Xr are:

  • USRE44186

Qternmet Xr was authorised for market use on 02 May, 2019.

Qternmet Xr is available in tablet, extended release;oral dosage forms.

Qternmet Xr can be used as treatment of type 2 diabetes mellitus.

The generics of Qternmet Xr are possible to be released after 12 November, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 2, 2022


Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus


More Information on Dosage

QTERNMET XR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic